Tags : Discover


AstraZeneca Selects AI-Generated CKD Target Under its Collaboration with BenevolentAI

Shots: AstraZeneca has selected a novel CKD target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter its portfolio In 2019, companies collaborated to discover new drugs for CKD and IPF The collaboration leverages AstraZeneca’s scientific expertise and rich datasets with BenevolentAI’s target identification platform to […]Read More


Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific

Shots: Merus to receive $40M up front, $20M as an equity investment, ~$540M as development & commercial milestones making it a total of $1.6B for three products, along with royalties, following the commercialization of therapies Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development, […]Read More


AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and

Shots: Frontier to receive$55M up front and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products. The company might get ~45M within the first 12mos. of collaboration Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs whereas […]Read More


Eisai Sign a Research Agreement with Wren Therapeutics to Discover

Shots: The companies entered into an exclusive research agreement for the discovery of novel small molecules targeting α-synuclein for the potential treatment of synucleinopathies including PD and dementia with Lewy bodies The collaboration will use Wren’s network kinetics drug discovery platform along with Eisai’s experience in drug discovery for neurodegenerative disorders, to accelerate the development […]Read More


Schrödinger Signs a $2.7B Agreement with BMS to Develop and

Shots: Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical, development, regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration The collaboration will merge Schrödinger’s computational platform […]Read More


Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for

Shots: BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform Boehringer Ingelheim gets an option to negotiate an exclusive right to biomarkers discovered under the collaboration. The XMarker platform supports the phage therapy for IBD, BX002, via analysis of real-world metagenomic […]Read More


Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will […]Read More